Edition:
United States

Daiichi Sankyo Co Ltd (4568.T)

4568.T on Tokyo Stock Exchange

2,466JPY
1:00am EST
Change (% chg)

¥0 (+0.00%)
Prev Close
¥2,466
Open
¥2,457
Day's High
¥2,480
Day's Low
¥2,445
Volume
1,939,100
Avg. Vol
2,607,355
52-wk High
¥2,750
52-wk Low
¥2,078

Latest Key Developments (Source: Significant Developments)

Kite Pharma establishes strategic partnership with Daiichi Sankyo
Monday, 9 Jan 2017 04:23pm EST 

Kite Pharma Inc : Kite Pharma establishes strategic partnership with Daiichi Sankyo to develop and commercialize axicabtagene ciloleucel (kte-c19) in Japan . Kite Pharma - Daiichi Sankyo will make an upfront payment to kite of $50 million . Kite Pharma says will be eligible to receive future payments totaling up to $200 million for development and commercial milestones . Kite Pharma says is also entitled to receive sales royalties in the low to mid double digit range .Kite pharma - under terms, Daiichi Sankyo will be responsible for development and commercialization of axicabtagene ciloleucel in Japan.  Full Article

R&I affirms Daiichi Sankyo Co Ltd's rating at "AA" and announces negative outlook -R&I
Tuesday, 27 Dec 2016 01:35am EST 

Daiichi Sankyo Co Ltd <4568.T> : Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "AA" -R&I .Rating outlook negative -R&I.  Full Article

U.S. FDA grants designation for HER2-targeting antibody drug conjugate DS-8201
Thursday, 1 Dec 2016 08:00am EST 

Daiichi Sankyo Co Ltd <4568.T>: u.s. Fda grants fast track designation for her2-targeting antibody drug conjugate ds-8201 for her2-positive metastatic breast cancer .Daiichi sankyo -fda grantd fast track designation to investigational her2-targeting antibody drug conjugate ds-8201 for her2-positive metastatic breast cancer.  Full Article

Daiichi Sankyo Co and Inspirion Delivery Sciences LLC Announce U.S. Licensing Agreement for MorphaBond
Tuesday, 25 Oct 2016 09:00am EDT 

Daiichi Sankyo Co Ltd <4568.T>: Daiichi And Inspirion Delivery Sciences LLC announce U.S. Licensing agreement for morphabond formulated with sentrybond abuse-deterrent technology . Under terms of agreement inspirion will receive an upfront payment .Inspiron will also receive milestone payments and royalties under terms of agreement.  Full Article

Daiichi Sankyo Co Ltd, Dana-Farber Cancer Institute today announce lung cancer research collaboration
Wednesday, 12 Oct 2016 08:00am EDT 

Daiichi Sankyo Co Ltd <4568.T>: Daiichi Sankyo Co Ltd - co, Dana-Farber Cancer Institute today announced a preclinical research collaboration focused on lung cancer .Daiichi Sankyo Co Ltd - financial terms of agreement were not disclosed.  Full Article

Daiichi Sankyo Co enters into a collaboration with Agonox Inc
Tuesday, 4 Oct 2016 08:00am EDT 

Daiichi Sankyo Co Ltd <4568.T>: Financial terms of agreement were not disclosed. . Daiichi Sankyo and Agonox will collaborate on preclinical development of program of an undisclosed immuno-oncology target .Entered into a strategic collaboration with Agonox, Inc.  Full Article

Daiichi Sankyo plans 5th&6th series unsecured corporate bonds worth total 100 bln yen
Friday, 15 Jul 2016 12:57am EDT 

Daiichi Sankyo Co Ltd <4568.T> : Says it plans to issue 5th series unsecured corporate bonds worth 75 billion yen, with coupon rate of 0.810 percent and maturity date on July 25, 2036 . Says it plans to issue 6th series unsecured corporate bonds worth 25 billion yen, with coupon rate of 1.200 percent and maturity date on July 25, 2046 .Subscription date on July 15 and payment date on July 25.  Full Article

Amgen and Daiichi Sankyo agree to commercialize Biosimilars in Japan
Wednesday, 13 Jul 2016 09:00pm EDT 

Amgen Inc : Amgen and daiichi sankyo announce agreement to commercialize biosimilars in japan . Under terms of agreement, amgen will remain responsible for development and manufacturing of biosimilars . Daiichi sankyo will file for marketing approval and be responsible for distribution and commercialization in japan . Amgen will have a limited right to co-promote products . Will retain all additional distribution and commercialization rights for biosimilar programs outside of japan . Specific financial terms of agreement were not disclosed .Deal includes several biosimilars in late-stage development, including biosimilars of adalimumab, bevacizumab and trastuzumab..  Full Article

UCB's Vimpat gets Japanese approval
Monday, 4 Jul 2016 02:36am EDT 

UCB SA : UCB and Daiichi Sankyo <4568.T> announce Japanese approval of lacosamide (brand name Vimpat) as adjunctive therapy in treatment partial-onset seizures in adult patients with epilepsy . UCB and Daiichi Sankyo will jointly commercialize lacosamide in Japan . ucb will manufacture and supply product; Daiichi Sankyo will manage distribution and book sales in Japan, with both companies promoting lacosamide in Japan .Approval reinforces commitment of both companies to improve lives of people in Japan living with epilepsy.  Full Article

Daiichi Sankyo plans 28 mln shares repurchase
Monday, 20 Jun 2016 04:11am EDT 

Daiichi Sankyo Co Ltd <4568.T> :Says it plans to buy 28 million shares (4.1 percent outstanding) back, for up to 500 million yen, from June 21 to Oct. 28.  Full Article

BRIEF-Kite Pharma establishes strategic partnership with Daiichi Sankyo

* Kite Pharma establishes strategic partnership with Daiichi Sankyo to develop and commercialize axicabtagene ciloleucel (kte-c19) in Japan